Page 87 - NPPA full book

Company Focus on innovation and development of focused treatment therapies

• Enjoys a leadership position with a market share of 52% in the Paracetamol 650 mg category

• Caripill is considered as a wonder drug in the management of dengue worldwide
• Portfolio comprises oral solids, oral liquids, topicals and insect ables for Cardiology, Daibetology,
Micro Labs
Anti pyretic, paediatric, Dental, Gynaecology, Neurology, Gastro enterology and ortho
therapeutic areas

• NATCO Pharma led to the development of the first generic Imatinib (VEENAT) for treatment of
Chronic Myeloid Leukaemia (CML)

• NATCO Pharma’s efforts led to the manufacturing of generic Sorafenib, the multi-kinase
targeted therapy through compulsory licensing benefitting thousands of liver cancer patients,
NATCO Pharma the first in the treatment of liver cancer

• Today, there are multiple such targeted generic therapies available in India for the treatment of
Liver & Kidney cancer

• Together with Bill and Melinda Gates Foundation introduced MenAfriVac vaccine in Africa for
Serum Institute
of India (SII) Meningitis A for a price of just US$0.50 per vaccination which helped the elimination of the
disease

• Developed a range of novel products called ‘sprinkle formulations’ for people who have

difficulty in swallowing tablets. Launched in versions of Metoprolol (cardiology), Rosuvastatin
Sun (cardiology) & Duloxetine (neuro-psychiatry)
Pharmaceutical • World’s first licensed ready to administer bag for oncology treatment

Industries
• Developed chemotherapy product in a premixed ready-to-infuse formulation

• Introduced Emrok and Emrok O (oral formulation) anti-MRSA (Methicillin-Resistant
Wockhardt
Staphylococcus Aureus) antibiotics to reduce mortality in hospitalized patients worldwide

• Developed Exemptia, world’s first biosimilar in 2014, a much-needed therapy for patients
suffering with inflammatory arthritis
• Introduced Saroglitzar drug ‘Bylipsa’ for NAFLD (Non-Alcoholic Fatty Liver Disease) and NASH
(Non-Alcoholic Steatohepatitis) in 2020
• Developed the next generation anti-rabies therapy TwinRab in association with WHO
Zydus
Lifesciences • Launched Ujvira in 2021, the world’s first Antibody Drug Conjugate (ADC) biosimilar of
Trastuzumab Emtansine for treating HER2 positive Breast Cancer

• Introduced Oxemia, an oral alternative to injectable in anaemia in Chronic Kidney Disease
(CKD)
• Lipaglyn (2019) - Zydus became the very first company to launch its own NCE. Lipaglyn is India’s
first Lab to market novel drug for diabetic dyslipidemia patents

77